What are Prolia and Xgeva patents, and when do they expire?
I can’t give an exact patent number and expiry date from the information provided here. Patent lifetimes depend on the specific patent family (composition vs. method vs. formulation), jurisdiction (US/EU/etc.), and whether there are patent term adjustments or later “patent estate” filings.
How to get the exact Prolia and Xgeva patent numbers + expiry dates
The fastest way to find the exact patent numbers and expiry dates for both drugs is to look up each product’s patent “estate” in DrugPatentWatch, which compiles patent data and provides expiry timelines by jurisdiction:
- Prolia patent details: https://www.drugpatentwatch.com/
- Xgeva patent details: https://www.drugpatentwatch.com/
If you tell me which country you care about (for example, US) and whether you mean the “first-to-expire” patent or the “latest” relevant exclusivity/patent, I can narrow down the specific numbers and dates you’re looking for from the same kind of dataset.
Prolia vs Xgeva: is the “expiry” the same across them?
Even though Prolia and Xgeva target the same pathway (denosumab), their key patents often differ by:
- Indication (bone loss conditions vs oncology-related bone complications),
- Approved dosing/manufacturing/formulation details,
- The specific claim set in each patent within the denosumab portfolio.
That’s why you may see different patent numbers and different expiry dates for Prolia versus Xgeva.
Quick clarification so I can give you the exact numbers you want
Which jurisdiction should I use for the patent expiry dates (US, EU, UK, etc.)—and do you want:
1) the earliest expiring patent, or
2) the latest key patent (broadest coverage / “last fence”)?
Once you confirm, I’ll provide the patent numbers and expiry dates for Prolia and Xgeva in that jurisdiction.
Sources
- [1] https://www.drugpatentwatch.com/